Skip to content
AnalystLens

Thermo Fisher Scientific 8-K Report, Financial Results (Jan 31, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 31, 2024
Period End
January 31, 2024
Security
TMO
In the record · 2016–202610-K1110-Q338-K153

TMO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 153 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’18Aug ’18
  2. Leadership change8-K · Nov ’20Nov ’20
  3. Material agreement8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed January 31, 2024. Cited figures are marked; the original filing is the authoritative source.

Thermo Fisher Scientific (TMO) reported fourth-quarter and full-year 2023 results on January 31, 2024, showing a clear year-over-year revenue decline driven by the post-pandemic normalization in COVID-19 testing and weaker demand in its Life Sciences Solutions segment.

Q4 revenue fell 5% to $10.89 billiona (Core organic growth -4%), while full-year revenue declined 5% to $42.86 billion (Core organic growth +1%). GAAP diluted EPS rose 5% in Q4 to $4.20, but full-year GAAP EPS fell to $15.45 from $17.63 and adjusted EPS fell to $21.55 from $23.24, reflecting lower volumes, higher restructuring charges ($459 million vs. $114 million) and higher interest expense ($1.375 billion vs. $726 million) tied to acquisition financing. Cash generation remained strong, with full-year operating cash flow of $8.41 billion and free cash flow of $7.01 billion, up about 1% from 2022.

Management returned $3.5 billionb to shareholders through buybacks ($3.0 billion) and dividends ($523 million) and completed the acquisitions of The Binding Site and CorEvitas, while announcing the pending acquisition of Olink Holding AB. Full-year 2024 guidance calls for revenue of $42.1 to $43.3 billion and adjusted EPS of $20.95 to $22.00, implying roughly flat to modestly lower results versus 2023 and signaling that management expects only a gradual recovery.

For investors, the key takeaways are the continued softness in Life Sciences Solutions and the step-down in profitability, offset by resilient Analytical Instruments growth (up 10%c for the year), Specialty Diagnostics margin expansion, and the company's strong cash flow and capital return capacity. Net debt has increased with the acquisition activity, so the pace of the Olink integration and the timing of demand recovery in bioprocessing and academic markets will be the main variables to monitor.

02—Key points

Key Highlights

  1. Q4 2023 revenue fell 5% year over year to $10.89 billion, with Core organic growth of -4%, while GAAP diluted EPS rose 5% to $4.20 on 70 basis points of operating margin expansion.
  2. Full-year 2023 revenue declined 5% to $42.86 billion; Core organic growth was +1%, with COVID-19 testing revenue of $0.33 billion versus a much larger contribution in 2022.
  3. Full-year GAAP diluted EPS fell to $15.45 from $17.63, and adjusted EPS fell to $21.55 from $23.24, as adjusted operating margin contracted 160 basis points to 22.9%.
  4. Life Sciences Solutions revenue dropped 26% for the year to $9.98 billion, while Analytical Instruments grew 10% to $7.26 billion and Specialty Diagnostics declined 8% to $4.41 billion.
  5. Interest expense nearly doubled to $1.38 billion from $726 million, and restructuring charges quadrupled to $459 million, weighing on GAAP earnings.
  6. Free cash flow was $7.01 billion, up 1%, and the company returned $3.5 billion to shareholders through $3.0 billion of buybacks and $523 million of dividends.
  7. 2024 guidance projects revenue of $42.1 to $43.3 billion and adjusted EPS of $20.95 to $22.00, and the pending Olink acquisition remains an important future catalyst.

03—Questions

Frequently Asked Questions

  1. How did Thermo Fisher perform in the fourth quarter of 2023?

    Revenue declined 5% to $10.89 billion, and Core organic growth was -4%. GAAP diluted EPS rose 5% to $4.20 and adjusted EPS rose 5% to $5.67, driven by operating margin expansion of 70 basis points on a GAAP basis and 100 basis points on an adjusted basis.

  2. Why did full-year earnings decline despite relatively flat Core organic growth?

    Reported revenue fell 5% and the adjusted operating margin contracted to 22.9% from 24.5%, reflecting lower COVID-19 testing revenue and weaker Life Sciences Solutions demand. Higher interest expense of $1.38 billion (versus $726 million) and restructuring costs of $459 million also reduced GAAP EPS to $15.45.

  3. What is the 2024 outlook?

    Management guided to 2024 revenue of $42.1 to $43.3 billion and adjusted EPS of $20.95 to $22.00. At the midpoint, this implies roughly flat revenue and a slight decline in adjusted EPS compared with 2023.

  4. How strong is the company's cash flow and capital return position?

    Operating cash flow was $8.41 billion and free cash flow was $7.01 billion for 2023. The company returned $3.5 billion to shareholders, though cash and equivalents declined to $8.08 billion and long-term obligations rose to $31.3 billion amid acquisition financing.

  5. What acquisition activity should investors be aware of?

    During 2023, Thermo Fisher completed the acquisitions of The Binding Site and CorEvitas and announced a pending agreement to acquire Olink Holding AB. Acquisitions consumed $3.66 billion of cash in 2023, and integration execution and the expected benefits of Olink will be key items to watch.

04—Continue

← View all 8-K filings